Günther Weindl
banner
weindl-lab.bsky.social
Günther Weindl
@weindl-lab.bsky.social
Professor of Pharmacology and Toxicology @UniBonn |
#pharmacology #signaling #immunopharmacology #innateimmunity #inflammation #autophagy
Reposted by Günther Weindl
So excited that this study is now online! It's been a pleasure to work with BioAge Labs and our collaborators on this story. We characterise a new class of #NLRP3 inhibitors with translational potential for so many inflammatory diseases.
#NLRP3 is a target for antiinflammatory therapies & can be inhibited by the tool compound MCC950. Wilhelmsen, @colllab.bsky.social et al characterize new small-molecule inhibitors, BAL-0028 & BAL-0598, that have a distinct mechanism of action & binding site. rupress.org/jem/article/...
#Inflammasome
September 2, 2025 at 4:22 PM
Reposted by Günther Weindl
Beyond excited to share our #NewPaper in @cellcellpress.bsky.social! Inflamed environments acidify intracellular #pH. BRD4 senses this via transcriptional condensates, tuning #macrophage responses to match demand and consequences of #inflammation authors.elsevier.com/sd/article/S...
July 22, 2025 at 1:24 PM
Reposted by Günther Weindl
Are there spatial restrictions in NLRP3 #inflammasome activation? I am super excited to share our new study spearheaded by amazing @elvirab.bsky.social
www.nature.com/articles/s41...
Clustering of NLRP3 induced by membrane or protein scaffolds promotes inflammasome assembly - Nature Communications
NLRP3 inflammasome activation is critical for the induction of protective immunity, but molecular insights are still lacking. Here, the authors express NLRP3 variants targeted to different cellular lo...
www.nature.com
May 27, 2025 at 8:40 AM
Reposted by Günther Weindl
A landmark success! The University of Bonn secured funding for all six existing Clusters of Excellence and both new initiatives – more than any other German university. More: www.uni-bonn.de/en/news/095-...

© G. Hübl, V. Lannert, M. Thürbach/ECONtribute, J. F. Saba/UKB, S. Wegener/ML4Q; N. Wietrich
May 22, 2025 at 4:08 PM
Reposted by Günther Weindl
A study in Nature Immunology uses a model of lipopolysaccharide injection in humans to characterize the transcriptomic landscape of bone marrow and blood immune cells during the hyperinflammatory and immunosuppressed phases of systemic inflammation. go.nature.com/44bj71Y
April 27, 2025 at 7:26 PM
TLR4 endocytosis and endosomal TLR4 signaling are distinct and independent outcomes of TLR4 activation | EMBO reports www.embopress.org/doi/full/10....
TLR4 endocytosis and endosomal TLR4 signaling are distinct and independent outcomes of TLR4 activation | EMBO reports
imageimageContrary to the prevailing model, ligand-induced TLR4 endocytosis is not a prerequisite for endosomal TLR4 signaling in macrophages. TLR4 endocytosis requires the TIR domain, PLCγ2, SYK and ...
www.embopress.org
April 13, 2025 at 6:09 PM
Reposted by Günther Weindl
What do Pablo Picasso and Charles Janeway have in common? Both were interested in patterns of life. Janeway was focused on pathogen associated molecular patterns (PAMPs) that are detected by our immune system. But what are these patterns he refers to?
March 8, 2025 at 2:39 PM
Reposted by Günther Weindl
#compchem
New work by Valerij Talagayev, Gerhard Wolber and me using tauRAMD to characterize unbinding paths of TLR8 agonist and antagonists. Interestingly, some ligands showed clear path preference:...
chemrxiv.org/engage/chemr...
March 7, 2025 at 1:37 PM
Our paper is out! Could the #nucleotide adenosine 5′-tetraphosphate (Ap4) promote #inflammation? Ap4 triggers IL-1β release distinct from canonical #inflammasome activators, shedding light on its potential role in #inflammaging. Kudos to Judith, Jonas, and collaborators! 👏 doi.org/10.1186/s100...
The vasoconstrictor adenosine 5′-tetraphosphate is a danger signal that induces IL-1β - Molecular Medicine
Background The endogenous nucleotide adenosine 5′-tetraphosphate (Ap4) is a potent vasoconstrictor. Despite its structural similarity to the danger signal adenosine 5’-triphosphate (ATP), the immunomo...
doi.org
February 21, 2025 at 8:40 AM
🚀 Our latest paper is out in J Med Chem @acsmedi.bsky.social! 🔥 Huge kudos to first authors Troy & Valerij and the amazing teams of @gwolber.bsky.social & Matej Sova for this fantastic collaboration! 🙌 #DrugDiscovery #InnateImmunity #Autoimmune 🔗 pubs.acs.org/doi/full/10.1021/acs.jmedchem.4c03148
Discovery of Novel Isoxazole-Based Small-Molecule Toll-Like Receptor 8 Antagonists
Toll-like receptor 8 (TLR8) recognizes viral and bacterial RNA, initiating inflammatory responses that are crucial for innate immunity. Dysregulated TLR8 signaling contributes to autoimmune diseases, including systemic lupus erythematosus and rheumatoid arthritis, driving chronic inflammation and tissue damage. Therefore, targeting TLR8 has gained attention as a promising therapeutic strategy. We report a novel selective TLR8 antagonist scaffold identified through computational modeling and simulation. In silico-guided rational drug design and synthesis led to potent isoxazole-based compounds that were characterized by structure–activity relationships. The most active compounds inhibited TLR8-mediated signaling in cell lines and primary cells, reduced MyD88 recruitment, suppressed NF-κB- and IRF-dependent signaling, and decreased inflammatory responses. In silico and pharmacological analyses demonstrated competitive binding to the pocket of chemical ligands within the TLR8 dimerization interface. These highly selective and potent TLR8 antagonists possess favorable physicochemical properties, representing potential clinical candidates for TLR8-targeted therapy.
pubs.acs.org
February 14, 2025 at 3:40 PM
Reposted by Günther Weindl
A Review in Nature Medicine explores the state-of-the-art applications of artificial intelligence in small-molecule drug development, from target identification and drug synthesis up to clinical trial design and conduct. https://go.nature.com/4jFyuVG 🔒
February 2, 2025 at 2:31 PM
Reposted by Günther Weindl
www.cell.com/immunity/ful... - 👉ISD investigators now defined a mechanism whereby HDAC9 regulates activation of the NLRP3 inflammasome and developed a targeted anti-inflammatory approach for treating atherosclerosis. #HDAC9 #cell #immunity
January 29, 2025 at 8:09 AM
Reposted by Günther Weindl
A human metabolic map of pharmacological perturbations reveals drug modes of action - @zampierilab.bsky.social @depbiomedicine.bsky.social go.nature.com/3CreANg
A human metabolic map of pharmacological perturbations reveals drug modes of action - Nature Biotechnology
Mapping the metabolic effects of drugs helps define their mode of action.
go.nature.com
January 28, 2025 at 3:42 PM
🔔 Happy to share our latest study showing that LPS-neutralizing #peptides fine-tune P2X receptor signaling to control #inflammation. 🔥 Kudos to first author Jonas and all collaborators! 👏 #pharmacology #inflammasome
pubs.acs.org/articlesonre...
Lipopolysaccharide-Neutralizing Peptide Modulates P2X7 Receptor-Mediated Interleukin-1β Release
Lipopolysaccharide (LPS)-neutralizing peptides are emerging as new potential therapeutic modalities to treat sepsis and skin infections. Purinergic ligand-gated ion channels (P2X receptors) play a critical role in various biological processes, including inflammation. Recent drug development efforts have significantly focused on the modulation of P2X receptors. Here, we investigated the effects of the synthetic LPS-neutralizing peptide Pep19–2.5 on human P2X receptors in cells of the innate immune system. Pep19–2.5 concentration-dependently triggered Ca2+ influx, interleukin (IL)-1β, and lactate dehydrogenase (LDH) release in Toll-like receptor-stimulated human macrophages and monocytes. Ca2+ influx was mediated at least partially by P2X7 receptors, and IL-1β and LDH release by P2X7 receptors, respectively. Confocal microscopy confirmed the colocalization of Pep19–2.5 with P2X7 receptors. Pep19–2.5-induced IL-1β release in primed cells was dependent on K+ efflux, caspase-1, and the nucleotide-binding oligomerization domain-like receptor family pyrin domain-containing protein 3 inflammasome. In the presence of the P2X7 receptor agonist 2′(3′)-O-(4-benzoylbenzoyl)adenosine-5′-triphosphate, Pep19–2.5 reduced IL-1β and LDH release. In 1321N1, astrocytoma cells stably transfected with human P2X receptors, Pep19–2.5 potently modulated P2X7 and P2X4 receptors (IC50 values of 0.346 and 0.146 μM, respectively) but showed less (P2X1, P2X3) or no activity (P2X2) at other P2X receptor subtypes. Our findings underline the potential of LPS-neutralizing peptides as modulators of P2X receptors, thus expanding their applicability beyond the treatment of sepsis to the treatment of inflammatory diseases.
pubs.acs.org
December 23, 2024 at 12:40 PM
Reposted by Günther Weindl
Mirror Bacteria: The biggest future threat to life on Earth. Leading scientists are raising the alarm before it becomes reality. Honored to play a small role in evaluating this work prior to publication.
www.science.org/doi/10.1126/...
Confronting risks of mirror life
Broad discussion is needed to chart a path forward.
www.science.org
December 13, 2024 at 2:18 AM
Reposted by Günther Weindl
Very happy to share our latest work just published in @jexpmed.bsky.social! #Firstpost

rupress.org/jem/article/...

Our amazing PhD student @lbernaleau.bsky.social shows that CCDC134 controls TLR biogenesis through the ER-chaperone Gp96. #ImmunoSky #innateimmunity #inflammation

Quick summary here:
CCDC134 controls TLR biogenesis through the ER chaperone Gp96 | Journal of Experimental Medicine | Rockefeller University Press
A loss-of-function genetic screen identifies the ER-resident protein CCDC134 as an essential regulator of Toll-like receptor (TLR) responses. CCDC134 binds
rupress.org
December 10, 2024 at 3:48 PM
Reposted by Günther Weindl

SurfDock: a surface-informed diffusion generative model for protein–ligand docking excels in accuracy, generalizability, and flexible ligand handling. It identified 7 novel ALDH1B1 inhibitors, showcasing its drug discovery potential.
nature.com/articles/s41...
Preprint: biorxiv.org/content/10.1...
SurfDock is a surface-informed diffusion generative model for reliable and accurate protein–ligand complex prediction - Nature Methods
SurfDock is a method for predicting protein–ligand complex structures by leveraging multimodal protein information and generative diffusion frameworks. Its results can be generalized to unseen protein...
nature.com
November 27, 2024 at 3:28 PM
Reposted by Günther Weindl
The danger theory of immunity strikes back... rdcu.be/d1uQN
November 26, 2024 at 6:13 PM
Reposted by Günther Weindl
Tlr7 drives sex differences in age- and Alzheimer’s disease–related demyelination

www.science.org/doi/10.1126/...
Tlr7 drives sex differences in age- and Alzheimer’s disease–related demyelination
Alzheimer’s disease (AD) and other age-related disorders associated with demyelination exhibit sex differences. In this work, we used single-nuclei transcriptomics to dissect the contributions of sex ...
www.science.org
November 29, 2024 at 4:50 AM
🎓 PhD Opening 🎓

We are looking for top candidates for a PhD on #immunomodulation of ‘cryptic’ host defense #peptides. Join #GRK2873 @unibonn.bsky.social @UKBonn 🧪 #PhD #Pharmacology #InnateImmunity #DFG

Project starts Oct 2025. Let's connect!

👇

www.grk2873.uni-bonn.de/en/training-...
PhD Application 2025
The Graduate Research Training Group 2873 “Tools and Drugs of the Future – Innovative Methods and New Modalities in Medicinal Chemistry”, funded by the German Research Foundation (DFG) offers 12 PhD P...
www.grk2873.uni-bonn.de
November 28, 2024 at 12:35 PM
Reposted by Günther Weindl
Acute suppression of mitochondrial ATP production prevents apoptosis and provides an essential signal for NLRP3 inflammasome activation
www.cell.com/immunity/ful...
Acute suppression of mitochondrial ATP production prevents apoptosis and provides an essential signal for NLRP3 inflammasome activation
Mitochondria control metabolism, cell death, and innate immunity, yet their reciprocal mechanistic connections are elusive, as is the conserved physiological function of the NLRP3 inflammasome. Saller...
www.cell.com
November 20, 2024 at 10:48 PM
How to target and degrade #NLRP3? Excited to share our study led by the fantastic Gütschow lab and Geyer lab! Check out the preprint: doi.org/10.26434/che...
#inflammasome #Inflammation #PROTACs #DrugDiscovery
November 22, 2024 at 8:12 AM